Abstract

AbstractThe North Qôroq centre comprises a series of concentric nepheline syenite intrusions and forms part of the Igaliko Nepheline Syenite Complex, in the rift-related Gardar Province of South Greenland. The North Qôroq syenites range from mildly undersaturated augite syenite to strongly peralkaline agpaitic nepheline syenite. Extensivein situfractional crystallization has been postulated for the chemical variation both within units and throughout the centre. Many of the rocks have been affected by metasomatic fluids associated with the emplacement of younger syenite units, and this complicates their interpretation. In this study, the trends and compositions exhibited by pyroxene and amphibole from North Qôroq are examined and related to either primary crystallization or metasomatic activity (e.g. controls offO2, peralkalinity). Implications thus drawn are used to interpret the chemical processes inherent in the chemical and fluid evolution of alkaline magmas, and, in particular, the transition from miaskitic to agpaitic magmatism. In general, the major phases of the North Qôroq syenites records the increasing evolution of the units by crystal fractionation, towards peralkaline compositions. The composition of olivine, in the least evolved syenites, also points to a relatively high state of fractionation of the parent magma, whilst pyroxene and amphibole record an overall decrease in Mg/Mg+Fe), and a general increase in Fe3+and alkali content, with increased fractionation. The increasing peralkalinity of the magma also governs the evolution of pyroxene and, to a lesser degree, amphibole towards higher Zr and Ti contents in the more Na-rich compositions. The trends for pyroxene from metasomatized syenite show similar patterns, but lower Fe2+enrichment, suggesting the source of the metasomatic fluids is similar to the evolving syenites. The presence of amphiboles in metasomatic rocks, and high F contents attest to the F-rich nature of the metasomatic fluids, which is in agreement with results previously reported for metasomatic fluorapatite.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.